131) We have shown previously that withaferin A (WA), a bioactive component of the medicinal plant Withania somnifera, inhibits growth of cultured and xenografted human breast cancer cells and prevents breast cancer development and pulmonary metastasis incidence in a transgenic mouse model. |
PMID:24293234 DOI:10.1002/mc.22110 |
2015 Molecular carcinogenesis |
* Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. |
- We have shown previously that withaferin A (WA), a bioactive component of the medicinal plant Withania somnifera, inhibits growth of cultured and xenografted human breast cancer cells and prevents breast cancer development and pulmonary metastasis incidence in a transgenic mouse model. The present study was undertaken to determine if the anticancer effect of WA involved inhibition of epithelial-mesenchymal transition (EMT). Experimental EMT induced by exposure of MCF-10A cells to tumor necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β) was partially reversed by treatment with WA but not by its structural analogs withanone or withanolide A. Combined TNF-α and TGF-β treatments conferred partial protection against MCF-10A cell migration inhibition by WA. Inhibition of TNF-α and TGF-β-induced MCF-10A cell migration by WA exposure was modestly attenuated by knockdown of E-cadherin protein. MCF-7 and MDA-MB-231 cells exposed to WA exhibited sustained (MCF-7) or transient (MDA-MB-231) induction of E-cadherin protein. On the other hand, the level of vimentin protein was increased markedly after 24 h treatment of MDA-MB-231 cells with WA. WA-induced apoptosis was not affected by vimentin protein knockdown in MDA-MB-231 cells. Protein level of vimentin was significantly lower in the MDA-MB-231 xenografts as well as in MMTV-neu tumors from WA-treated mice compared with controls. The major conclusions of the present study are that (a) WA treatment inhibits experimental EMT in MCF-10A cells, and (b) mammary cancer growth inhibition by WA administration is associated with suppression of vimentin protein expression in vivo. |
(1)69 and | (12)5 at | (25)3 models | (36)2 model |
(2)48 factor | (13)4 but | (26)3 or | (37)2 modeling |
(3)48 of | (14)4 during | (27)3 traits | (38)2 outcomes |
(4)41 *null* | (15)4 factor, | (28)3 trajectories | (39)2 phase |
(5)32 in | (17)4 patterns | (29)2 among | (40)2 properties |
(6)25 factors | (18)4 plate | (30)2 are | (41)2 responses |
(7)9 inhibition | (19)4 response | (31)2 as | (42)2 restriction |
(8)8 rate | (20)4 was | (32)2 dynamics | (43)2 stunting |
(9)6 factors, | (21)3 cone | (33)2 effects | (44)2 to |
(10)6 rates | (22)3 curve | (34)2 forest | (45)2 velocities |
(11)5 arrest | (23)3 factor-C | (35)2 hormone | (46)2 were |
add keyword